Il cross linking, Abstract relazione di Cosimo Mazzotta (visualizza CV):
Il cross linking
Riboflavin UV-A Corneal Crosslinking was developed in the 1990’s to treat progressive keratoconus. Its indication was rapidly extended to iatrogenic corneal ectasias. Conventional 3mW/cm2 CXL represented the gold standard therapy in multiple Countries around the World to halt the progression of early stages corneal ectasia demonstrating good long-term visual results and low complications. Early diagnosis, slowing the progression of keratoconus turning to native corneal crosslinking spirit: stabilizing ectasia progression preventing corneal shape modification, is the Key. New Epi-Off and Epi-On Iontophoresis Accelerated CXL protocols demonstrated a medium-long term improvement in visual and topo-aberrometric parameters reducing treatment time and increasing patient’s compliance. New conservative approaches such as topography-guided CXL and CXL-plus corneal reshaping techniques are suitable for patients with poor spectacles corrected visual acuity and contact lenses intolerance before considering lamellar and penetrating keratoplasty.